In AML RAS pathway Mutations Confer Worse Outcome in IDH1 and IDH2 Mutated AML Patients Receiving Hematopoietic Stem Cell Transplantation

被引：0
|
作者：
Beinicke, Stefanie
Grimm, Juliane
Jentzsch, Madlen
Bill, Marius
Hantschel, Janine
Goldmann, Karoline
Schulz, Julia
Cross, Michael
Franke, Georg-Nikolaus
Vucinic, Vladan
Ponisch, Wolfram
Behre, Gerhard
Niederwieser, Dietger
Schwind, Sebastian
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2037
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The prognostic impact of RAS pathway mutations in Acute Myeloid Leukemia (AML) patients (pts) with IDH1 or IDH2 mutations undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
    Beinicke, S.
    Grimm, J.
    Jentzsch, M.
    Bill, M.
    Haentschel, J.
    Goldmann, K.
    Schulz, J.
    Cross, M.
    Franke, G. -N.
    Vucinic, V.
    Poenisch, W.
    Behre, G.
    Niederwieser, D.
    Schwind, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 59 - 60
  • [2] IDH1 and IDH2 Mutations in Gliomas, AML, and Intrahepatic Cholangiocarcinoma
    Wachsmann, M. B.
    Hatanpaa, J.
    Chen, W.
    Hammer, S.
    Ram, R.
    Oliver, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1031 - 1032
  • [3] IDH1/IDH2 mutations predict survival in glioma and AML
    Hegi, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S2 - S2
  • [4] Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
    Kunadt, Desiree
    Stasik, Sebastian
    Metzeler, Klaus H.
    Roellig, Christoph
    Schliemann, Christoph
    Greif, Philipp A.
    Spiekermann, Karsten
    Rothenberg-Thurley, Maja
    Krug, Utz
    Braess, Jan
    Kraemer, Alwin
    Hochhaus, Andreas
    Scholl, Sebastian
    Hilgendorf, Inken
    Bruemmendorf, Tim H.
    Jost, Edgar
    Steffen, Bjoern
    Bug, Gesine
    Einsele, Hermann
    Goerlich, Dennis
    Sauerland, Cristina
    Schaefer-Eckart, Kerstin
    Krause, Stefan W.
    Haenel, Mathias
    Hanoun, Maher
    Kaufmann, Martin
    Woermann, Bernhard
    Kramer, Michael
    Sockel, Katja
    Egger-Heidrich, Katharina
    Herold, Tobias
    Ehninger, Gerhard
    Burchert, Andreas
    Platzbecker, Uwe
    Berdel, Wolfgang E.
    Mueller-Tidow, Carsten
    Hiddemann, Wolfgang
    Serve, Hubert
    Stelljes, Matthias
    Baldus, Claudia D.
    Neubauer, Andreas
    Schetelig, Johannes
    Thiede, Christian
    Bornhaeuser, Martin
    Middeke, Jan M.
    Stoelzel, Friedrich
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [5] Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
    Desiree Kunadt
    Sebastian Stasik
    Klaus H. Metzeler
    Christoph Röllig
    Christoph Schliemann
    Philipp A. Greif
    Karsten Spiekermann
    Maja Rothenberg-Thurley
    Utz Krug
    Jan Braess
    Alwin Krämer
    Andreas Hochhaus
    Sebastian Scholl
    Inken Hilgendorf
    Tim H. Brümmendorf
    Edgar Jost
    Björn Steffen
    Gesine Bug
    Hermann Einsele
    Dennis Görlich
    Cristina Sauerland
    Kerstin Schäfer-Eckart
    Stefan W. Krause
    Mathias Hänel
    Maher Hanoun
    Martin Kaufmann
    Bernhard Wörmann
    Michael Kramer
    Katja Sockel
    Katharina Egger-Heidrich
    Tobias Herold
    Gerhard Ehninger
    Andreas Burchert
    Uwe Platzbecker
    Wolfgang E. Berdel
    Carsten Müller-Tidow
    Wolfgang Hiddemann
    Hubert Serve
    Matthias Stelljes
    Claudia D. Baldus
    Andreas Neubauer
    Johannes Schetelig
    Christian Thiede
    Martin Bornhäuser
    Jan M. Middeke
    Friedrich Stölzel
    Journal of Hematology & Oncology, 15
  • [6] Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
    Bill, Marius
    Jentzsch, Madlen
    Bischof, Lara
    Kohlschmidt, Jessica
    Grimm, Juliane
    Schmalbrock, Laura Katharina
    Backhaus, Donata
    Brauer, Dominic
    Goldmann, Karoline
    Franke, Georg -Nikolaus
    Vucinic, Vladan
    Niederwieser, Dietger
    Mims, Alice S.
    Platzbecker, Uwe
    Eisfeld, Ann-Kathrin
    Schwind, Sebastian
    BLOOD ADVANCES, 2023, 7 (03) : 436 - 444
  • [7] IDH1 (BUT NOT IDH2) MUTATIONS CAUSE INFERIOR OUTCOME IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETICS
    Markova, J.
    Michkova, P.
    Salek, C.
    Brezinova, J.
    Maaloufova, J. Soukupova
    Soukup, P.
    Cetkovsky, P.
    Michalova, K.
    Schwarz, J.
    HAEMATOLOGICA, 2015, 100 : 371 - 371
  • [8] AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series
    Benton, Christopher Brent
    Ravandi, Farhad
    Andreeff, Michael
    Kantarjian, Hagop
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] INCIDENCE AND TYPE OF IDH1 AND IDH2 MUTATIONS IN AML-NK PATIENTS AND THEIR PROGNOSTIC IMPACT ON TREATMENT OUTCOME
    Kim, H. J.
    Kim, Y. K.
    Kook, H.
    Lee, I. K.
    Kim, N.
    Kim, D. D. H.
    Kim, H. J.
    Jung, C. W.
    Jang, J. H.
    Moon, J. H.
    Sohn, S. K.
    Won, J. H.
    Kim, S. H.
    Huh, J.
    Jung, S. H.
    Ahn, J. S.
    Yang, D. H.
    Lee, J. J.
    HAEMATOLOGICA, 2014, 99 : 298 - 299
  • [10] Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors
    Largeaud, Laetitia
    Berard, Emilie
    Bertoli, Sarah
    Dufrechou, Stephanie
    Prade, Nais
    Gadaud, Noemie
    Tavitian, Suzanne
    Bories, Pierre
    Luquet, Isabelle
    Sarry, Audrey
    De Mas, Veronique
    Huguet, Francoise
    Delabesse, Eric
    Recher, Christian
    LEUKEMIA RESEARCH, 2019, 81 : 82 - 87
12345